Prof Michael Hofman
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
612 Scholarly works
20 Projects
HIGHLIGHTS
2027
Research grants (ARC, NHMRC, MRFF)
Improving Prostate Cancer Outcomes by Integrating Novel Imaging and Targeted Therapy (Theranostics) for Personalised Medicine
2026
Journal article
Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis
DOI: 10.1016/j.clgc.2026.1026282022
Research grants (ARC, NHMRC, MRFF)
Personalised Medicine to Improve Outcomes for Men With Prostate Cancer Through Seamless Integration of Novel Imaging and Targeted Therapy (Theranostics)
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Journal article
Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
DOI: 10.2967/jnumed.117.1995542017
Journal article
Prostate-specific membrane antigen ligands for imaging and therapy
DOI: 10.2967/jnumed.116.1867672017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.002
RECENT SCHOLARLY WORKS
2026
Journal article
Adaptive auxiliary task learning for medical image segmentation under scarce training data
DOI: 10.1016/j.compmedimag.2026.1028142026
Journal article
Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study
DOI: 10.1016/j.tranon.2026.1028712026
Journal article
Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer
DOI: 10.1111/bju.702832026
Journal article
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies
DOI: 10.2967/jnumed.126.2720852026
Journal article
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT
DOI: 10.2967/jnumed.125.2719952026
Journal article
Germline CDK12 variants in aggressive prostate cancer.
DOI: 10.1158/2159-8290.CD-26-00842026
Journal article
Clonal Hematopoiesis after177 Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
DOI: 10.1016/S1470-2045(26)00120-8